RIGEL PHARMACEUTICALS, INC. Revenue
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Revenue of $78.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-04
- RIGEL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $78.70M, a 22.60% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $58.82M, a 10.28% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $69.80M, a 21.19% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $69.46M, a 25.59% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $294.28M, a 64.15% increase from fiscal 2024.
- RIGEL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $179.28M, a 53.38% increase from fiscal 2023.
- RIGEL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $116.88M, a 2.79% decline from fiscal 2022.
- RIGEL PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $120.24M, a 19.43% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $78.70M 10-Q · filed 2026-08-04 | $137.52M 10-Q · filed 2026-08-04 | $207.32M derived: sum of 3 quarters · filed 2026-08-04 | $276.79M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $58.82M 10-Q · filed 2026-05-05 | $128.62M derived: sum of 2 quarters · filed 2026-05-05 | $198.08M derived: sum of 3 quarters · filed 2026-05-05 | $299.77M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $69.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $139.26M derived: sum of 2 quarters · filed 2026-03-03 | $240.95M derived: sum of 3 quarters · filed 2026-08-04 | $294.28M 10-K · filed 2026-03-03 |
| 2025-09-30 | $69.46M 10-Q · filed 2025-11-04 | $171.15M derived: sum of 2 quarters · filed 2026-08-04 | $224.48M 10-Q · filed 2025-11-04 | $282.08M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $101.69M 10-Q · filed 2026-08-04 | $155.02M 10-Q · filed 2026-08-04 | $212.61M derived: sum of 3 quarters · filed 2026-08-04 | $267.92M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $53.33M 10-Q · filed 2026-05-05 | $110.93M derived: sum of 2 quarters · filed 2026-05-05 | $166.24M derived: sum of 3 quarters · filed 2026-05-05 | $203.08M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $57.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $112.90M derived: sum of 2 quarters · filed 2026-03-03 | $149.74M derived: sum of 3 quarters · filed 2026-03-03 | $179.28M 10-K · filed 2026-03-03 |
| 2024-09-30 | $55.31M 10-Q · filed 2025-11-04 | $92.15M derived: sum of 2 quarters · filed 2025-11-04 | $121.68M 10-Q · filed 2025-11-04 | $157.47M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $36.84M 10-Q · filed 2025-08-05 | $66.38M 10-Q · filed 2025-08-05 | $102.17M derived: sum of 3 quarters · filed 2026-03-03 | $130.30M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $29.53M 10-Q · filed 2025-05-06 | $65.33M derived: sum of 2 quarters · filed 2026-03-03 | $93.46M derived: sum of 3 quarters · filed 2026-03-03 | $120.35M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $35.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $63.93M derived: sum of 2 quarters · filed 2026-03-03 | $90.81M derived: sum of 3 quarters · filed 2026-03-03 | $116.88M 10-K · filed 2026-03-03 |
| 2023-09-30 | $28.13M 10-Q · filed 2024-11-07 | $55.02M derived: sum of 2 quarters · filed 2024-11-07 | $81.09M 10-Q · filed 2024-11-07 | $132.37M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | $26.89M 10-Q · filed 2024-08-06 | $52.96M 10-Q · filed 2024-08-06 | $104.23M derived: sum of 3 quarters · filed 2025-03-04 | $126.64M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | $26.07M 10-Q · filed 2024-05-07 | $77.35M derived: sum of 2 quarters · filed 2025-03-04 | $99.76M derived: sum of 3 quarters · filed 2025-03-04 | $129.58M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $51.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $73.69M derived: sum of 2 quarters · filed 2025-03-04 | $103.51M derived: sum of 3 quarters · filed 2025-03-04 | $120.24M 10-K · filed 2025-03-04 |
| 2022-09-30 | $22.41M 10-Q · filed 2023-11-07 | $52.23M derived: sum of 2 quarters · filed 2023-11-07 | $68.96M 10-Q · filed 2023-11-07 | $89.37M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $29.82M 10-Q · filed 2023-08-01 | $46.55M 10-Q · filed 2023-08-01 | $66.96M derived: sum of 3 quarters · filed 2024-03-05 | $88.51M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $16.73M 10-Q · filed 2023-05-02 | $37.14M derived: sum of 2 quarters · filed 2024-03-05 | $58.69M derived: sum of 3 quarters · filed 2024-03-05 | $84.95M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $20.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $41.95M derived: sum of 2 quarters · filed 2024-03-05 | $68.22M derived: sum of 3 quarters · filed 2024-03-05 | $149.24M 10-K · filed 2024-03-05 |
| 2021-09-30 | $21.54M 10-Q · filed 2022-11-03 | $47.81M derived: sum of 2 quarters · filed 2022-11-03 | $128.83M 10-Q · filed 2022-11-03 | $147.28M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $26.27M 10-Q · filed 2022-08-02 | $107.28M 10-Q · filed 2022-08-02 | $125.73M derived: sum of 3 quarters · filed 2022-08-02 | $144.12M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $81.02M 10-Q · filed 2022-05-03 | $99.47M derived: sum of 2 quarters · filed 2022-05-03 | $117.86M derived: sum of 3 quarters · filed 2022-05-03 | $133.88M derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | $18.45M 10-K · filed 2021-03-02 | $36.84M derived: sum of 2 quarters · filed 2021-11-02 | $52.86M derived: sum of 3 quarters · filed 2021-11-02 | $108.62M 10-K · filed 2023-03-07 |
| 2020-09-30 | $18.39M 10-Q · filed 2021-11-02 | $34.41M derived: sum of 2 quarters · filed 2021-11-02 | $90.17M 10-Q · filed 2021-11-02 | $105.57M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $16.02M 10-Q · filed 2021-08-03 | $71.78M 10-Q · filed 2021-08-03 | $87.18M derived: sum of 3 quarters · filed 2021-08-03 | $108.04M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $55.76M 10-Q · filed 2021-05-05 | $71.16M derived: sum of 2 quarters · filed 2021-05-05 | $92.02M derived: sum of 3 quarters · filed 2021-05-05 | $102.42M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $15.40M 10-K · filed 2021-03-02 | $36.26M derived: sum of 2 quarters · filed 2021-03-02 | $46.66M derived: sum of 3 quarters · filed 2021-03-02 | $59.29M 10-K · filed 2022-03-01 |
| 2019-09-30 | $20.86M 10-K · filed 2021-03-02 | $31.26M derived: sum of 2 quarters · filed 2021-03-02 | $43.89M 10-Q · filed 2020-11-05 | $81.75M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-06-30 | $10.41M 10-K · filed 2021-03-02 | $23.03M 10-Q · filed 2020-08-04 | $60.89M derived: sum of 3 quarters · filed 2021-03-02 | $65.75M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-03-31 | $12.62M 10-K · filed 2021-03-02 | $50.48M derived: sum of 2 quarters · filed 2021-03-02 | $55.35M derived: sum of 3 quarters · filed 2021-03-02 | $57.13M derived: sum of 4 quarters · filed 2021-03-02 |
| 2018-12-31 | $37.86M 10-K · filed 2020-02-27 | $42.72M derived: sum of 2 quarters · filed 2020-02-27 | $44.51M derived: sum of 3 quarters · filed 2020-02-27 | $44.51M 10-K · filed 2021-03-02 |
| 2018-09-30 | $4.87M 10-K · filed 2020-02-27 | $6.65M derived: sum of 2 quarters · filed 2020-02-27 | $6.65M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $1.79M 10-K · filed 2020-02-27 | $1.79M 10-Q · filed 2019-08-06 | ||
| 2017-12-31 | $4.48M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | $900.00K 10-K · filed 2019-02-28 | |||
| 2017-03-31 | $3.58M 10-K · filed 2019-02-28 | |||
| 2016-12-31 | $20.38M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |